Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marek Kujawa is active.

Publication


Featured researches published by Marek Kujawa.


Cancer Research | 2009

Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response

Angelika Szokalska; Marcin Makowski; Dominika Nowis; Grzegorz M. Wilczynski; Marek Kujawa; Cezary Wójcik; Izabela Młynarczuk-Biały; Pawel Salwa; Jacek Bil; Sylwia Janowska; Patrizia Agostinis; Tom Verfaillie; Marek Bugajski; Jan Gietka; Tadeusz Issat; Eliza Glodkowska; Piotr Mrowka; Tomasz Stoklosa; Michael R. Hamblin; Pawel Mroz; Marek Jakóbisiak; Jakub Golab

Photodynamic therapy (PDT) is an approved therapeutic procedure that exerts cytotoxic activity toward tumor cells by inducing production of reactive oxygen species such as singlet oxygen. PDT leads to oxidative damage of cellular macromolecules, including proteins that undergo multiple modifications such as fragmentation, cross-linking, and carbonylation that result in protein unfolding and aggregation. Because the major mechanism for elimination of carbonylated proteins is their degradation by proteasomes, we hypothesized that a combination of PDT with proteasome inhibitors might lead to accumulation of carbonylated proteins in endoplasmic reticulum (ER), aggravated ER stress, and potentiated cytotoxicity toward tumor cells. We observed that Photofrin-mediated PDT leads to robust carbonylation of cellular proteins and induction of unfolded protein response. Pretreatment of tumor cells with three different proteasome inhibitors, including bortezomib, MG132, and PSI, gave increased accumulation of carbonylated and ubiquitinated proteins in PDT-treated cells. Proteasome inhibitors effectively sensitized tumor cells of murine (EMT6 and C-26) as well as human (HeLa) origin to PDT-mediated cytotoxicity. Significant retardation of tumor growth with 60% to 100% complete responses was observed in vivo in two different murine tumor models (EMT6 and C-26) when PDT was combined with either bortezomib or PSI. Altogether, these observations indicate that combination of PDT with proteasome inhibitors leads to potentiated antitumor effects. The results of these studies are of immediate clinical application because bortezomib is a clinically approved drug that undergoes extensive clinical evaluations for the treatment of solid tumors.


American Journal of Pathology | 2010

Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib

Dominika Nowis; Michał Mączewski; Urszula Mackiewicz; Marek Kujawa; Anna Ratajska; Mariusz R. Wieckowski; Grzegorz M. Wilczynski; Monika Malinowska; Jacek Bil; Pawel Salwa; Marek Bugajski; Cezary Wójcik; Maciej Siński; Piotr Abramczyk; Magdalena Winiarska; Anna Dąbrowska-Iwanicka; Jerzy Duszyński; Marek Jakóbisiak; Jakub Golab

Recent case reports provided alarming signals that treatment with bortezomib might be associated with cardiac events. In all reported cases, patients experiencing cardiac problems were previously or concomitantly treated with other chemotherapeutics including cardiotoxic anthracyclines. Therefore, it is difficult to distinguish which components of the therapeutic regimens contribute to cardiotoxicity. Here, we addressed the influence of bortezomib on cardiac function in rats that were not treated with other drugs. Rats were treated with bortezomib at a dose of 0.2 mg/kg thrice weekly. Echocardiography, histopathology, and electron microscopy were used to evaluate cardiac function and structural changes. Respiration of the rat heart mitochondria was measured polarographically. Cell culture experiments were used to determine the influence of bortezomib on cardiomyocyte survival, contractility, Ca(2+) fluxes, induction of endoplasmic reticulum stress, and autophagy. Our findings indicate that bortezomib treatment leads to left ventricular contractile dysfunction manifested by a significant drop in left ventricle ejection fraction. Dramatic ultrastructural abnormalities of cardiomyocytes, especially within mitochondria, were accompanied by decreased ATP synthesis and decreased cardiomyocyte contractility. Monitoring of cardiac function in bortezomib-treated patients should be implemented to evaluate how frequently cardiotoxicity develops especially in patients with pre-existing cardiac conditions, as well as when using additional cardiotoxic drugs.


The International Journal of Biochemistry & Cell Biology | 2008

Decreased ER-associated degradation of α-TCR induced by Grp78 depletion with the SubAB cytotoxin

Agnieszka Lass; Marek Kujawa; Elizabeth J. McConnell; Adrienne W. Paton; James C. Paton; Cezary Wójcik

HeLa cells stably expressing the alpha chain of T-cell receptor (alphaTCR), a model substrate of ER-associated degradation (ERAD), were used to analyze the effects of BiP/Grp78 depletion by the SubAB cytotoxin. SubAB induced XBP1 splicing, followed by JNK phosphorylation, eIF2alpha phosphorylation, upregulation of ATF3/4 and partial ATF6 cleavage. Other markers of ER stress, including elements of ERAD pathway, as well as markers of cytoplasmic stress, were not induced. SubAB treatment decreased absolute levels of alphaTCR, which was caused by inhibition of protein synthesis. At the same time, the half-life of alphaTCR was extended almost fourfold from 70 min to 210 min, suggesting that BiP normally facilitates ERAD. Depletion of p97/VCP partially rescued SubAB-induced depletion of alphaTCR, confirming the role of VCP in ERAD of alphaTCR. It therefore appears that ERAD of alphaTCR is driven by at least two different ATP-ase systems located at two sides of the ER membrane, BiP located on the lumenal side, while p97/VCP on the cytoplasmic side. While SubAB altered cell morphology by inducing cytoplasm vacuolization and accumulation of lipid droplets, caspase activation was partial and subsided after prolonged incubation. Expression of CHOP/GADD153 occurred only after prolonged incubation and was not associated with apoptosis.


Biochemical Pharmacology | 2015

SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress

Angelika Muchowicz; Malgorzata Firczuk; Malgorzata Wachowska; Marek Kujawa; Ewa Jankowska-Steifer; Magdalena Gabrysiak; Zofia Pilch; Szymon Klossowski; Ryszard Ostaszewski; Jakub Golab

Thioredoxins (Trx) together with thioredoxin reductases (TrxR) participate in the maintenance of protein thiol homeostasis and play cytoprotective roles in tumor cells. Therefore, thioredoxin-thioredoxin reductase system is considered to be a promising therapeutic target in cancer treatment. We have previously reported that SK053, a peptidomimetic compound targeting the thioredoxin-thioredoxin reductase system, induces oxidative stress and demonstrates antitumor activity in mice. In this study, we investigated the mechanisms of SK053-mediated tumor cell death. Our results indicate that SK053 induces apoptosis of Raji cells accompanied by the activation of the endoplasmic reticulum (ER) stress and induction of unfolded protein response. Incubation of tumor cells with SK053 induces increase in BiP, CHOP, and spliced XBP-1 levels, which precede induction of apoptosis. CHOP-deficient (CHOP(-/-)) mouse embryonic fibroblasts are more resistant to SK053-induced apoptosis as compared with normal fibroblasts indicating that the apoptosis of tumor cells depends on the expression of this transcription factor. Additionally, the ER-stress-induced apoptosis, caused by SK053, is strongly related with Trx expression levels. Altogether, our results indicate that SK053 induces ER stress-associated apoptosis and reveal a link between thioredoxin inhibition and induction of UPR in tumor cells.


Histochemistry and Cell Biology | 2018

Cells with hematopoietic potential reside within mouse proepicardium

Ewa Jankowska-Steifer; Justyna Niderla-Bielińska; Bogdan Ciszek; Marek Kujawa; Mateusz Bartkowiak; Aleksandra Flaht-Zabost; Daria Klosinska; Anna Ratajska

During embryonic development, hematopoietic cells are present in areas of blood-vessel differentiation. These hematopoietic cells emerge from a specific subpopulation of endothelial cells called the hemogenic endothelium. We have previously found that mouse proepicardium contained its own population of endothelial cells forming a network of vascular tubules. We hypothesize that this EC population contains cells of hematopoietic potential. Therefore, we investigated an in vitro hematopoietic potential of proepicardial cell populations. The CD31+/CD45−/CD71− cell population cultured for 10 days in MethocultTM gave numerous colonies of CFU-GEMM, CFU-GM, and CFU-E type. These colonies consisted of various cell types. Flk-1+/CD31−/CD45−/CD71−, and CD45+ and/or CD71+ cell populations produced CFU-GEMM and CFU-GM, or CFU-GM and CFU-E colonies, respectively. Immunohistochemical evaluations of smears prepared from colonies revealed the presence of cells of different hematopoietic lineages. These cells were characterized by labeling with various combinations of antibodies directed against CD31, CD41, CD71, c-kit, Mpl, Fli1, Gata-2, and Zeb1 markers. Furthermore, we found that proepicardium-specific marker WT1 co-localized with Runx1 and Zeb1 and that single endothelial cells bearing CD31 molecule expressed Runx1 in the proepicardial area of embryonic tissue sections. We have shown that cells of endothelial and/or hematopoietic phenotypes isolated from mouse proepicardium possess hematopoietic potential in vitro and in situ. These results are supported by RT-PCR analyses of proepicardial extract, which revealed the expression of mRNA for crucial regulatory factors for hemogenic endothelium specification, i.e., Runx1, Notch1, Gata2, and Sox17. Our data are in line with previous observation on hemangioblast derivation from the quail PE.


Molecular Biology of the Cell | 2006

Valosin-containing protein (p97) is a regulator of endoplasmic reticulum stress and of the degradation of N-end rule and ubiquitin-fusion degradation pathway substrates in mammalian cells

Cezary Wojcik; Maga Rowicka; Andrzej Kudlicki; Dominika Nowis; Elizabeth J. McConnell; Marek Kujawa


Archives of Microbiology | 2007

Hoc protein regulates the biological effects of T4 phage in mammals

Krystyna Dabrowska; Maria Zembala; Kinga Switala-Jelen; Joanna Wietrzyk; Adam Opolski; Katarzyna Szczaurska; Marek Kujawa; Joanna Godlewska; Andrzej Górski


Gene Expression Patterns | 2006

Temporal/spatial expression and efflux activity of ABC transporter, P-glycoprotein/Abcb1 isoforms and Bcrp/Abcg2 during early murine development

Wojciech Sawicki; Marek Kujawa; Ewa Jankowska-Steifer; Ewa T. Mystkowska; Anna Hyc; Cezary Kowalewski


Experimental and Molecular Pathology | 2005

Quantitative ultrastructural changes in satellite cells of rats immobilized after soleus muscle denervation

Marek Kujawa; Wojciech Baran; Ewa Jankowska-Steifer


Respiratory Care | 2011

Comparison of Airway Wall Remodeling in Asthma and COPD: Biopsy Findings

Justyna Kosciuch; Rafał Krenke; Katarzyna Górska; Wojciech Baran; Marek Kujawa; Katarzyna Hildebrand; Ryszarda Chazan

Collaboration


Dive into the Marek Kujawa's collaboration.

Top Co-Authors

Avatar

Wojciech Baran

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Katarzyna Górska

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar

Katarzyna Hildebrand

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar

Ryszarda Chazan

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar

Jakub Golab

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar

Rafał Krenke

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anna Ratajska

Medical University of Warsaw

View shared research outputs
Top Co-Authors

Avatar

Dominika Nowis

Medical University of Warsaw

View shared research outputs
Researchain Logo
Decentralizing Knowledge